Blueberry Therapeutics is an innovation driven Biopharmaceutical Company that was
started up in 2011 by Dr John Ridden and Dr Mike Davies who between them have
almost 40 years of Pharmaceutical R&D experience. Blueberry’s ambition is to take
compounds through preclinical research on to clinical proof of concept in both
humans and companion animals eventually resulting in positive clinical proof of
concepts which will be partnered with large or medium sized pharmaceutical
companies for Phase III and marketing.
Blueberry’s research and development strategy is to develop new therapeutic
approaches targeting well-established drug targets to meet unmet medical needs in
inflammatory and infection-associated conditions. Initially there are three areas of
focus: bacterial Multi-Drug Resistance, Fungal Nail Infection, and Atopic Dermatitis /
Inflammatory Bowel Disease.
Blueberry is focused on targeting well-validated drug targets using potent peptide
aptamers and small molecule drugs delivered using a novel non-toxic nanoparticle
delivery system. In addition, Blueberry will employ cutting-edge adaptive clinical trial
designs to expedite clinical delivery in humans and companion animals. In this way,
Blueberry expects to avoid much of the late stage efficacy failures experienced by
drug developers.
Blueberry’s move into the new AZ BioHub at Alderley Park marks the initiation of our
full-time research and development activities in state of the art laboratories. Moving
into the BioHub will have many benefits for Blueberry and the BioHub. As a
symbiotic relationship we will see Blueberry and the BioHub grow over the following
years. Blueberry’s move into the BioHub will allow it to utilise our recently achieved
grants and private funding to employ expert scientists and support staff to drive our
compounds to important clinical end-points and therefore, ultimately treat patients
suffering from a range of terrible diseases with safe and effective new medicines.